Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses.
Fischer
Karl-Georg
KG
Deschler
Barbara
B
Lübbert
Michael
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000941:Antigens / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001327:Autoimmune Diseases / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D002081:Buttocks; D003520:Cyclophosphamide / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology; D017809:Fatal Outcome; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007273:Injections, Intramuscular / Q000009:adverse effects; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D008297:Male; D010314:Partial Thromboplastin Time; D010956:Plasmapheresis; D011241:Prednisone / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000941:Antigens; D001323:Autoantibodies; D001779:Blood Coagulation Factors; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; C042580:factor VII clotting antigen; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D005167:Factor VII; D005169:Factor VIII; C065655:anti-inhibitor coagulant complex; D011241:Prednisone